Corcept Therapeutics Incorporated

NasdaqCM:CORT Voorraadrapport

Marktkapitalisatie: US$5.9b

Corcept Therapeutics Toekomstige groei

Future criteriumcontroles 5/6

De verwachting is dat Corcept Therapeutics de winst en omzet met respectievelijk 41% en 22.6% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 38.3% per jaar.

Belangrijke informatie

41.0%

Groei van de winst

38.3%

Groei van de winst per aandeel

Pharmaceuticals winstgroei23.8%
Inkomstengroei22.6%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt01 Nov 2024

Recente toekomstige groei-updates

Recent updates

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Sep 28
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Sep 06
If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

Aug 01
Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

Apr 15
With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23
After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23
Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Corcept Therapeutics starts phase 2 trial of its ALS treatment

Oct 11

Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Sep 27
Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Winst- en omzetgroeiprognoses

NasdaqCM:CORT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20261,0423955103183
12/31/20258102242782325
12/31/20246911551981985
9/30/2024629140143145N/A
6/30/2024570125123124N/A
3/31/2024524117125125N/A
12/31/2023482105127127N/A
9/30/202345091154155N/A
6/30/202342894135135N/A
3/31/202341494111111N/A
12/31/2022402101120120N/A
9/30/2022398117136136N/A
6/30/2022392113151151N/A
3/31/2022380112177178N/A
12/31/2021366113167168N/A
9/30/2021353106153154N/A
6/30/202134398134135N/A
3/31/202134099143144N/A
12/31/2020354106151152N/A
9/30/2020356109164165N/A
6/30/2020351114173173N/A
3/31/2020335106145146N/A
12/31/201930694135136N/A
9/30/201928587108109N/A
6/30/201926878114115N/A
3/31/201925876104105N/A
12/31/201825175115116N/A
9/30/2018238152119119N/A
6/30/2018216148N/A85N/A
3/31/2018189142N/A86N/A
12/31/2017159129N/A61N/A
9/30/201713035N/A41N/A
6/30/201710924N/A39N/A
3/31/20179313N/A25N/A
12/31/2016818N/A18N/A
9/30/2016725N/A18N/A
6/30/2016641N/A10N/A
3/31/201656-2N/A8N/A
12/31/201550-6N/A3N/A
9/30/201544-11N/A-2N/A
6/30/201538-17N/A-9N/A
3/31/201532-22N/A-18N/A
12/31/201427-31N/A-27N/A
9/30/201422-39N/A-34N/A
6/30/201417-44N/A-36N/A
3/31/201413-48N/A-37N/A
12/31/201310-46N/A-37N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei CORT ( 41% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van CORT ( 41% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.4% per jaar).

Hoge groeiwinsten: De winst van CORT zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van CORT ( 22.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van CORT ( 22.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CORT naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven